According to current guidelines, renin-angiotensin-aldosterone system (RAAS) blockade with an angiotensin-converting enzyme (ACE) inhibitor or an angiotensin receptor blocker (ARB) should be considered in all patients presenting with ST-elevation myocardial infarction (STEMI) and is recommended for all ACS patients suffering from either arterial hypertension, chronic kidney disease, diabetes, or reduced left-ventricular ejection fraction [2, 3]. Here, ACE is linked to ST Elevation Myocardial Infarction.